- Home
- ARVN vs PEB Comparison
ARVN vs PEB Comparison
Compare ARVN & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- PEB
- Stock Information
- Founded
- ARVN 2015
- PEB 2009
- Country
- ARVN United States
- PEB United States
- Employees
- ARVN N/A
- PEB N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- PEB Real Estate Investment Trusts
- Sector
- ARVN Health Care
- PEB Real Estate
- Exchange
- ARVN Nasdaq
- PEB Nasdaq
- Market Cap
- ARVN 1.8B
- PEB 1.6B
- IPO Year
- ARVN 2018
- PEB 2009
- Fundamental
- Price
- ARVN $18.48
- PEB $13.56
- Analyst Decision
- ARVN Strong Buy
- PEB Buy
- Analyst Count
- ARVN 13
- PEB 6
- Target Price
- ARVN $63.00
- PEB $14.92
- AVG Volume (30 Days)
- ARVN 967.8K
- PEB 1.8M
- Earning Date
- ARVN 10-30-2024
- PEB 02-19-2025
- Dividend Yield
- ARVN N/A
- PEB 0.30%
- EPS Growth
- ARVN N/A
- PEB N/A
- EPS
- ARVN N/A
- PEB N/A
- Revenue
- ARVN $161,100,000.00
- PEB $1,449,797,000.00
- Revenue This Year
- ARVN $237.44
- PEB N/A
- Revenue Next Year
- ARVN N/A
- PEB $3.64
- P/E Ratio
- ARVN N/A
- PEB N/A
- Revenue Growth
- ARVN 1.07
- PEB 3.15
- 52 Week Low
- ARVN $17.37
- PEB $11.65
- 52 Week High
- ARVN $53.08
- PEB $16.65
- Technical
- Relative Strength Index (RSI)
- ARVN 32.78
- PEB 44.96
- Support Level
- ARVN $17.37
- PEB $13.25
- Resistance Level
- ARVN $19.21
- PEB $14.73
- Average True Range (ATR)
- ARVN 1.64
- PEB 0.44
- MACD
- ARVN -0.59
- PEB -0.17
- Stochastic Oscillator
- ARVN 11.80
- PEB 16.31
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,924 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.